Market closedNon-fractional
NeoGenomics/NEO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About NeoGenomics
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Ticker
NEO
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Providers and Services
Headquarters
Fort Myers, United States
Employees
2,100
Website
www.neogenomics.com
NeoGenomics Metrics
BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$0.67
EPS
1.16
Beta
-
Dividend rate
Price and volume
Market cap
$1.8B
Beta
1.16
Financial strength
Current ratio
7.481
Quick ratio
6.845
Long term debt to equity
65.377
Total debt to equity
65.863
Interest coverage (TTM)
-13.68%
Management effectiveness
Return on assets (TTM)
-3.49%
Return on equity (TTM)
-8.88%
Valuation
Price to revenue (TTM)
2.83
Price to book
1.89
Price to tangible book (TTM)
48.66
Price to free cash flow (TTM)
-43.62
Growth
Revenue change (TTM)
15.27%
Earnings per share change (TTM)
-33.73%
3-year revenue growth
10.39%
3-year earnings per share growth
89.56%
What the Analysts think about NeoGenomics
Analyst Ratings
Majority rating from 13 analysts.
NeoGenomics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$156M
0.45%
Net income
-$27M
88.81%
Profit margin
-17.28%
88.03%
NeoGenomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.05
-
$0.03
-$0.02
-
Expected
-$0.11
-$0.07
-$0.02
-$0.05
-$0.00
Surprise
-55.96%
-
-220.37%
-59.26%
-
NeoGenomics News
AllArticlesVideos
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
GlobeNewsWire·4 weeks ago
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
Business Wire·1 month ago
NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NeoGenomics stock?
NeoGenomics (NEO) has a market cap of $1.8B as of July 05, 2024.
What is the P/E ratio for NeoGenomics stock?
The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of July 05, 2024.
Does NeoGenomics stock pay dividends?
No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next NeoGenomics dividend payment date?
NeoGenomics (NEO) stock does not pay dividends to its shareholders.
What is the beta indicator for NeoGenomics?
NeoGenomics (NEO) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell NeoGenomics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.